nice.org.uk

GENEL
META
HTML
LİNK ANALİZİ
SUNUCU
IP

Nice.org.uk recives any estimated n/a unique visitors and n/a unique page views per day. Revenue gained from these much visits may be n/a per day from various advertising sources. The estimated worth of site is n/a.

Web Sitesi Yaşı n/a
Alexa Rank no-data
Ülke Ireland
IP Adresi 52.218.108.44

META BİLGİLERİ

Başlık

NICE | The National Inst**ute for Health and Care Excellence

Açıklama

Guidance, advice and information services for health, public health and social care professionals.

Anahtar Kelimeler

İçerik Türü

utf-8

No	Meta Adı	Değer
1	viewport	width=device-width, initial-scale=1

google ads

GENEL HTML BİLGİLERİ

Tür	Durum
HTML 5
Duyarlı Web Sitesi (Responsive)

HTML BOYUT BİLGİLERİ

HTML Size: 23.8 KB
Text Size: 2.9 KB
Code Size: 21 KB

İçerik / Kod Oranı 11.97 %

nice.org.uk web sitesinin içerik / kod oranı 11.97 %'dir. Arama motorları örümcekleri tarafından yeterli içeriğe sahip olmayan sayfalar genellikle pek fazla önem görmemektedirler.

ÖNEMLİ HTML ETİKETLERİ VE KULLANIM SAYILARI

Başlıklar

No	Metin
1	ımproving health and social care through evidence-based guidance

No	Metin
1	Latest guidance
2	Latest guidance in consultation

No	Metin
1	Browse guidance by area:
2	Explore nıce
3	Latest news
4	Tweets

Metin Stilleri

STRONG1
B0
EM0
I0
U0
CITE0

STRONG

No	Metin
1	Explore NICE

LİNK ANALİZİ

Toplam Bağlantı Sayısı: 43

İç Bağlantı Sayısı : 40

No	Metin	Tür
1	Find NICE guidance	text
2	Conditions and diseases	text
3	Health and social care delivery	text
4	Health protection	text
5	Lifestyle and wellbeing	text
6	Pop****tion groups	text
7	Settings	text
8	About us	text
9	Put guidance into practice	text
10	Find journals and databases	text
11	Financial planning	text
12	Get involved	text
13	Latest guidance	text
14	Larotrectinib for treating NTRK fusion-positive solid tumours	text
15	COVID 19 rapid evidence summary: Anakinra for COVID-19 a***ociated secondary haemophagocytic lymphohistiocytosis	text
16	COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19	text
17	COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19	text
18	Cytokine adsorption devices for treating respiratory failure in people with COVID-19	text
19	Latest guidance in consultation	text
20	News	text
21	About	text
22	Events	text
23	Get involved	text
24	-	image
25	Find out more about working for us	text
26	-	image
27	Find resources to help you put guidance into practice	text
28	-	image
29	View our antimicrobial prescribing guidelines	text
30	-	image
31	Support for industry to engage with us during health technology development	text
32	-	image
33	Watch our video about how we're reviewing the way we produce and present guidance	text
34	-	image
35	How we're supporting the NHS and social care to respond quickly to the challenges of the COVID-19 pandemic	text
36	Latest news	text
37	NICE recommends treatment for type of small-cell lung cancer	text
38	NICE chairman Sharmila Nebhrajani begins her new role	text
39	Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE	text
40	NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interst**ial lung disease	text